NRAS Mutation Analysis (Codons 12 & 13) in UAE | AED 1400 | DHA Approved

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert. INT/EGQ/2509DA/3139).
Premium Logistics: Hospital extraction only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Cold-chain transport for biopsy specimens.
Clinical Guidance: Telephonic post-test clinical guidance for result interpretation by DHA-licensed genetics specialists.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

NRAS mutation analysis targeting codons 12 and 13 by Sanger sequencing detects activating point mutations that serve as negative predictors for anti‑EGFR therapy in colorectal cancer and guide targeted treatment in melanoma, thyroid carcinoma, and haematological disorders. The test is performed on fresh tumour tissue biopsies obtained under sterile conditions within a hospital setting.

Feature	Our Test – NRAS Codon 12/13 Sanger	Closest Alternative – Broad NGS Panel
Precision	Gold‑standard single‑codon resolution; 99.9% analytical sensitivity at codons 12 & 13	Whole‑gene coverage; lower depth at individual hot‑spot codons
Methodology	Bi‑directional Sanger Sequencing with sequence‑specific PCR	Next‑Generation Sequencing (targeted panel)
Speed	7–8 working days	14–21 working days
Cost in UAE	AED 1400	AED 2500–5000
Regulatory Status	Fully DHA/MOHAP compliant under Federal Decree‑Law No. 45 of 2021 on Personal Data Protection and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.	Variable; may require extended informed consent

Physician Insight & Safety Protocols

“As a consultant in medical genetics, I have witnessed how NRAS mutation analysis empowers oncologists to refine treatment strategies for colorectal cancer patients. This targeted Sanger sequencing delivers clear, actionable results at codons 12 and 13, enabling precise anti‑EGFR therapy decisions. The test is performed on biopsy tissue collected in a hospital setting, ensuring specimen integrity and safety.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Advisory

🛑 Do not discontinue prescribed medication without consulting your doctor. Anticoagulant use must be communicated to the physician prior to biopsy.

Exclusion Criteria & Emergency Red Flags

Exclusion: Inability to obtain adequate tumour tissue (insufficient cellularity, extensive necrosis); patients with active bleeding diathesis or who cannot temporarily pause anticoagulants prior to biopsy; test must be ordered by a DHA-licensed oncologist or genetics specialist.
Emergency Red Flags: Immediately attend the nearest emergency department if, after a biopsy, you develop persistent bleeding, purulent discharge, fevers >38°C, or rapid swelling at the biopsy site.
UAE Legal Mandates: For minors (<18 years), genetic testing requires explicit consent from a legal guardian in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your data is protected under the UAE Personal Data Protection Law (Federal Decree‑Law No. 45 of 2021).

Patient FAQ & Clinical Guidance

1. What is the clinical utility of NRAS codon 12/13 mutation analysis?

NRAS codon 12/13 mutation analysis identifies activating mutations that predict lack of response to anti‑EGFR monoclonal antibodies in colorectal cancer, guiding first‑line targeted therapy decisions.

2. Do I need a doctor’s prescription for this test?

A physician’s prescription is required for all genetic tests, except for surgical clearance, pregnancy‑related protocols, and pre‑travel screening where a clinical justification form may be accepted under UAE health regulations.

3. How is the tumour tissue sample collected?

Tissue collection is performed by your surgeon or interventional radiologist in a hospital setting. No fasting or special preparation is needed, but inform your doctor of all anticoagulant use.

UAE Regulatory & Data Privacy Adherence

Your data is protected. DNA Labs UAE operates under DHA Facility License No. 1143. All patient information is handled in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical reporting adheres to standards set by the Dubai Health Authority and Ministry of Health and Prevention.

Clinical & Logistical Metadata

Test Name	NRAS Mutation Analysis (Codons 12 & 13) – Sanger Sequencing
Price (AED)	AED 1,400
Turnaround Time	7–8 working days
Sample Type / Matrix	Fresh tumour tissue (biopsy) – Hospital extraction only
Methodology Used	Bi‑directional Sanger Sequencing with sequence‑specific PCR
ICD-10-CM Code	C18.9 (Malignant neoplasm of colon, unspecified)
LOINC Code	52050-0 (NRAS gene targeted mutation analysis in Blood or Tissue by Sequencing)
DHA Facility License & Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE